000140511 001__ 140511
000140511 005__ 20240321220825.0
000140511 0247_ $$2doi$$a10.1016/j.neurobiolaging.2018.11.022
000140511 0247_ $$2pmid$$apmid:30616208
000140511 0247_ $$2pmc$$apmc:PMC6572755
000140511 0247_ $$2ISSN$$a0197-4580
000140511 0247_ $$2ISSN$$a1558-1497
000140511 0247_ $$2altmetric$$aaltmetric:52349038
000140511 037__ $$aDZNE-2020-06833
000140511 041__ $$aEnglish
000140511 082__ $$a610
000140511 1001_ $$0P:(DE-2719)2811820$$aVöglein, Jonathan$$b0$$eFirst author$$udzne
000140511 245__ $$aSeizures as an early symptom of autosomal dominant Alzheimer's disease.
000140511 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2019
000140511 264_1 $$2Crossref$$3print$$bElsevier BV$$c2019-04-01
000140511 3367_ $$2DRIVER$$aarticle
000140511 3367_ $$2DataCite$$aOutput Types/Journal article
000140511 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1707492936_2407
000140511 3367_ $$2BibTeX$$aARTICLE
000140511 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000140511 3367_ $$00$$2EndNote$$aJournal Article
000140511 520__ $$aOur objective was to assess the reported history of seizures in cognitively asymptomatic mutation carriers for autosomal dominant Alzheimer's disease (ADAD) and the predictive value of seizures for mutation carrier status in cognitively asymptomatic first-degree relatives of ADAD patients. Seizure occurrence in the Dominantly Inherited Alzheimer Network observational study was correlated with mutation carrier status in cognitively asymptomatic subjects. Of 276 cognitively asymptomatic individuals, 11 (4%) had experienced seizures, and nine of these carried an ADAD mutation. Thus, in the Dominantly Inherited Alzheimer Network population, seizure frequency in mutation carriers was significantly higher than in noncarriers (p = 0.04), and the positive predictive value of seizures for the presence of a pathogenic mutation was 81.8%. Among cognitively asymptomatic ADAD family members, the occurrence of seizures increases the a priori risk of 50% mutation-positive status to about 80%. This finding suggests that ADAD mutations increase the risk of seizures.
000140511 536__ $$0G:(DE-HGF)POF3-344$$a344 - Clinical and Health Care Research (POF3-344)$$cPOF3-344$$fPOF III$$x0
000140511 536__ $$0G:(DE-HGF)POF3-342$$a342 - Disease Mechanisms and Model Systems (POF3-342)$$cPOF3-342$$fPOF III$$x1
000140511 542__ $$2Crossref$$i2019-04-01$$uhttps://www.elsevier.com/tdm/userlicense/1.0/
000140511 588__ $$aDataset connected to CrossRef, PubMed,
000140511 650_2 $$2MeSH$$aAdult
000140511 650_2 $$2MeSH$$aAlzheimer Disease: complications
000140511 650_2 $$2MeSH$$aAlzheimer Disease: genetics
000140511 650_2 $$2MeSH$$aFemale
000140511 650_2 $$2MeSH$$aGenes, Dominant: genetics
000140511 650_2 $$2MeSH$$aGenetic Association Studies
000140511 650_2 $$2MeSH$$aHeterozygote
000140511 650_2 $$2MeSH$$aHumans
000140511 650_2 $$2MeSH$$aMale
000140511 650_2 $$2MeSH$$aMutation: genetics
000140511 650_2 $$2MeSH$$aObservational Studies as Topic
000140511 650_2 $$2MeSH$$aPredictive Value of Tests
000140511 650_2 $$2MeSH$$aRisk
000140511 650_2 $$2MeSH$$aSeizures: etiology
000140511 650_2 $$2MeSH$$aSeizures: genetics
000140511 7001_ $$aNoachtar, Soheyl$$b1
000140511 7001_ $$aMcDade, Eric$$b2
000140511 7001_ $$aQuaid, Kimberly A$$b3
000140511 7001_ $$aSalloway, Stephen$$b4
000140511 7001_ $$aGhetti, Bernardino$$b5
000140511 7001_ $$aNoble, James$$b6
000140511 7001_ $$aBerman, Sarah$$b7
000140511 7001_ $$aChhatwal, Jasmeer$$b8
000140511 7001_ $$aMori, Hiroshi$$b9
000140511 7001_ $$aFox, Nick$$b10
000140511 7001_ $$aAllegri, Ricardo$$b11
000140511 7001_ $$aMasters, Colin L$$b12
000140511 7001_ $$aBuckles, Virginia$$b13
000140511 7001_ $$aRingman, John M$$b14
000140511 7001_ $$aRossor, Martin$$b15
000140511 7001_ $$aSchofield, Peter R$$b16
000140511 7001_ $$aSperling, Reisa$$b17
000140511 7001_ $$0P:(DE-2719)2000010$$aJucker, Mathias$$b18$$udzne
000140511 7001_ $$0P:(DE-2719)2000055$$aLaske, Christoph$$b19$$udzne
000140511 7001_ $$aPaumier, Katrina$$b20
000140511 7001_ $$aMorris, John C$$b21
000140511 7001_ $$aBateman, Randall J$$b22
000140511 7001_ $$0P:(DE-2719)2811659$$aLevin, Johannes$$b23$$udzne
000140511 7001_ $$0P:(DE-2719)2810712$$aDanek, Adrian$$b24$$eLast author$$udzne
000140511 7001_ $$aNetwork, Dominantly Inherited Alzheimer$$b25
000140511 77318 $$2Crossref$$3journal-article$$a10.1016/j.neurobiolaging.2018.11.022$$b : Elsevier BV, 2019-04-01$$p18-23$$tNeurobiology of Aging$$v76$$x0197-4580$$y2019
000140511 773__ $$0PERI:(DE-600)1498414-3$$a10.1016/j.neurobiolaging.2018.11.022$$gVol. 76, p. 18 - 23$$p18-23$$q76<18 - 23$$tNeurobiology of aging$$v76$$x0197-4580$$y2019
000140511 8567_ $$2Pubmed Central$$uhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572755
000140511 8564_ $$uhttps://pub.dzne.de/record/140511/files/DZNE-2020-06833_Restricted.pdf
000140511 8564_ $$uhttps://pub.dzne.de/record/140511/files/DZNE-2020-06833_Restricted.pdf?subformat=pdfa$$xpdfa
000140511 909CO $$ooai:pub.dzne.de:140511$$pVDB
000140511 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811820$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000140511 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000010$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b18$$kDZNE
000140511 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000055$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b19$$kDZNE
000140511 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811659$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b23$$kDZNE
000140511 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810712$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b24$$kDZNE
000140511 9131_ $$0G:(DE-HGF)POF3-344$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vClinical and Health Care Research$$x0
000140511 9131_ $$0G:(DE-HGF)POF3-342$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vDisease Mechanisms and Model Systems$$x1
000140511 9141_ $$y2019
000140511 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-10$$wger
000140511 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROBIOL AGING : 2021$$d2022-11-10
000140511 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-10
000140511 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-10
000140511 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-10
000140511 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-10
000140511 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-10
000140511 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-10
000140511 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-10
000140511 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-10
000140511 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEUROBIOL AGING : 2021$$d2022-11-10
000140511 9201_ $$0I:(DE-2719)1110002$$kAG Höglinger 1$$lTranslational Neurodegeneration$$x0
000140511 9201_ $$0I:(DE-2719)1210001$$kAG Jucker$$lCell Biology of Neurological Diseases$$x1
000140511 9201_ $$0I:(DE-2719)1111016$$kAG Levin$$lClinical Neurodegeneration$$x2
000140511 9201_ $$0I:(DE-2719)7000003$$kU Clinical Researchers - München$$lU Clinical Researchers - München$$x3
000140511 980__ $$ajournal
000140511 980__ $$aVDB
000140511 980__ $$aI:(DE-2719)1110002
000140511 980__ $$aI:(DE-2719)1210001
000140511 980__ $$aI:(DE-2719)1111016
000140511 980__ $$aI:(DE-2719)7000003
000140511 980__ $$aUNRESTRICTED